Repare Therapeutics Inc. announced today the completion of the previously announced acquisition of all of the issued and outstanding common shares of the Company (the “Common Shares” and the holders of the Common Shares, the “Shareholders”) by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly “Xeno”) a non-profit biotechnology company, by way of a statutory plan of arrangement (the “Transaction” or the “Arrangement”).

Repare Therapeutics Inc. 今天宣布，此前宣布的由非营利性生物技术公司 XenoTherapeutics, Inc. 和 Xeno Acquisition Corp.（合称“Xeno”）通过法定安排计划（“交易”或“安排”）收购公司所有已发行和流通在外的普通股（“普通股”及普通股持有人，“股东”）已完成。

The Arrangement was approved by the Shareholders at a special meeting held on January 16, 2026, and a final order approving the Arrangement was issued by the Superior Court of Québec (Commercial Division) on January 23, 2026..

该协议已在2026年1月16日举行的特别股东大会上获得股东批准，并于2026年1月23日由魁北克高级法院（商业法庭）发出最终批准命令。

In accordance with the terms of the Arrangement, the Shareholders received a cash payment of approximately US$2.20 per Common Share that was determined based upon the Company’s cash balance immediately prior to the closing of the Transaction after deducting certain transaction costs, the aggregate amount of outstanding liabilities, and a transaction fee to Xeno.

根据协议条款，股东每股普通股获得约2.20美元的现金支付。该金额是基于交易完成前公司扣除特定交易成本、未偿负债总额及支付给Xeno的交易费用后的现金余额确定的。

In addition, each Shareholder received one non-transferable contingent value right (“CVR”) for each Common Share which represents the right to receive a pro rata portion of potential payments, in cash, described in, and subject to and in accordance with the terms and conditions of, the contingent value rights agreement dated January 28, 2026 among Xeno, Broadridge Corporate Issuer Solutions, LLC (“Broadridge”), in its capacity as rights agent, and WT Representative LLC, solely in its capacity as the initial representative, agent and attorney in-fact of the CVR holders..

此外，每位股东每持有一股普通股，便获得一份不可转让的或有价值权（“CVR”），该权利代表按比例获得潜在付款的权利，付款将以现金形式支付，具体描述见2026年1月28日签署的《或有价值权协议》，该协议由Xeno、Broadridge Corporate Issuer Solutions, LLC（“Broadridge”）作为权利代理，以及WT Representative LLC仅以其作为CVR持有者的初始代表、代理和事实上的律师身份共同订立，且受其条款和条件约束。

Consideration for the Common Shares has been remitted by or on behalf of Xeno to Broadridge, in its capacity as depositary under the Arrangement, and will be paid to former Shareholders of the Company as soon as reasonably practicable after the date hereof (or, in the case of registered Shareholders, as soon as reasonably practicable after a properly completed and signed letter of transmittal is received by the depositary together with the share certificate(s) and/or DRS Advice(s) representing Common Shares formerly held by them)..

普通股的对价已由Xeno或其代表支付给作为本次安排下的存管人的Broadridge，并将在本协议日期之后尽快支付给公司的前股东（或者，对于注册股东，则是在存管人收到正确填写并签署的转让信函以及代表其原先持有的普通股的股票证书和/或DRS通知后尽快支付）。

As a result of the completion of the Arrangement, it is expected that the Common Shares will cease trading on the Nasdaq Global Select Market on or about January 28, 2026, and the Company will subsequently file a Form 15 with the SEC requesting suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the U.S.

由于该协议的完成，预计普通股将在2026年1月28日左右停止在纳斯达克全球精选市场交易，随后公司将会向美国证券交易委员会提交一份表格15，要求暂停根据美国《证券法》第13条和第15(d)条规定的公司报告义务。

Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company will also deregister the Common Shares under the Exchange Act. The Company has applied to cease to be a reporting issuer in Québec pursuant to the securities legislation of Québec..

《1934年证券交易法》（经修订）（“交易法”）。公司还将根据交易法注销普通股。公司已根据魁北克的证券立法申请停止作为魁北克的报告发行人。

Further details regarding the Arrangement are provided in the definitive proxy statement on Schedule 14A in respect of the Transaction (the “Proxy Statement”), which is available on the Company's profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca.

有关该安排的更多详情，请参阅与交易相关的Schedule 14A最终委托书（“委托书”），该文件可在EDGAR网站www.sec.gov上的公司档案以及SEDAR+网站www.sedarplus.ca上查阅。

About Repare Therapeutics Inc.

关于Repare Therapeutics Inc.

Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair.

Repare Therapeutics是一家临床阶段的精准肿瘤学公司，其专有的合成致死方法助力了新型疗法的发现与开发。Repare Therapeutics专注于基因组不稳定性（包括DNA损伤修复）开发出了高度靶向的癌症治疗方法。

The Company’s clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor; and RP-1664, a Phase 1 PLK4 inhibitor..

公司的临床阶段管线包括 RP-3467，一种处于第一阶段的 Polθ ATPase 抑制剂；以及 RP-1664，一种处于第一阶段的 PLK4 抑制剂。

About XenoTherapeutics, Inc.

关于异种治疗公司

XenoTherapeutics, Inc. is a Massachusetts-based 501(c)(3) research foundation focused on advancing xenotransplantation through scientific research, clinical development, and public education. For more information, please visit www.xenotx.org.

XenoTherapeutics, Inc. 是一家位于马萨诸塞州的 501(c)(3) 研究基金会，致力于通过科学研究、临床开发和公众教育推动异种移植的发展。欲了解更多信息，请访问 www.xenotx.org。

Forward Looking Statements

前瞻性声明

This news release contains certain information which, as presented, constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable securities laws in Canada. All statements in this news release other than statements of historical facts are forward-looking statements and forward-looking information.

本新闻稿包含某些信息，按照其表述方式，构成1995年《私人证券诉讼改革法案》所指的“前瞻性陈述”，以及加拿大适用证券法所指的“前瞻性信息”。本新闻稿中的所有声明，除历史事实陈述外，均为前瞻性陈述和前瞻性信息。

These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words.

这些声明可能通过诸如“目标”、“预期”、“相信”、“可能”、“估计”、“预计”、“预测”、“目的”、“打算”、“或许”、“计划”、“可能”、“潜力”、“寻求”、“将要”等词语或类似表达来识别，这些词语旨在表明前瞻性声明，尽管并非所有前瞻性声明都包含这些词语。

Forward-looking statements in this news release include, but are not limited to, statements regarding the delisting of the Common Shares from the Nasdaq Global Select Market, the Company ceasing to be a reporting issuer under applicable Québec securities laws and the deregistration of the Common Shares under the U.S.

本新闻稿中的前瞻性陈述包括但不限于关于普通股从纳斯达克全球精选市场退市、公司根据适用的魁北克证券法不再作为报告发行人以及在美国注销普通股的陈述。

Securities Exchange Act of 1934, as amended. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this news release. Each of these forward-looking statements involves risks and uncertainties, many of which are outside of the control of Repare, that could cause the Company’s actual results to differ materially from those expressed or implied by the forward-looking statements.

《1934年证券交易法》（经修订）。这些前瞻性陈述是基于公司本新闻稿发布之日的预期和假设。每一项前瞻性陈述都涉及风险和不确定性，其中许多风险和不确定性是Repare无法控制的，可能导致公司的实际结果与前瞻性陈述中明示或暗示的结果存在重大差异。

Many factors may cause differences between current expectations and actual results, including, but not limited to those related to: (i) the possibility that the Common Shares will not be delisted from the Nasdaq Global Select Market within the .

可能导致当前预期与实际结果之间存在差异的因素有很多，包括但不限于：(i) 普通股可能不会在纳斯达克全球精选市场退市。

Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this news release are identified in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S.

可能导致公司实际结果与本新闻稿中前瞻性陈述所表达或暗示的结果不同的其他因素，已在公司截至2024年12月31日的年度报告Form 10-K中的“风险因素”部分进行了识别，并已提交给美国相关机构。

Securities and Exchange Commission (the “SEC”) and the Autorité des Marchés Financiers (Quebec) (“AMF”) on March 3, 2025, and in other filings made with the SEC and AMF from time to time, including the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law..

美国证券交易委员会（“SEC”）和魁北克金融市场管理局（“AMF”）于2025年3月3日，以及公司不时向SEC和AMF提交的其他文件，包括公司截至2025年9月30日的季度Form 10-Q报告。公司明确声明，除非法律另有要求，否则不承担更新本文中包含的任何前瞻性陈述的义务，无论是否因新信息、未来事件、情况变化或其他原因。

Contacts

联系人

Investor Relations & Media Contact:

投资者关系及媒体联系：

Matthew DeYoung

马修·德扬

Investor Relations and Media

投资者关系与媒体

Argot Partners

行话伙伴

investor@reparerx.com

投资者@修复药房.com

Source: businesswire.com

来源：businesswire.com